Drug intelligence / Profile preview

v-Src siRNA

Development stage
Unknown
Lead developer
Sigma Aldrich
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intraperitoneal
01

Overview

v-Src siRNA is a research-grade small interfering RNA designed to silence the expression of the v-Src oncogene, the transforming protein of the Rous Sarcoma Virus (RSV). v-Src is a constitutively active, membrane-associated tyrosine kinase that was the first oncogene to be discovered and serves as a critical model for understanding cellular transformation and cancer signaling. The siRNA functions through the RNA interference (RNAi) pathway, where it is incorporated into the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage and degradation of v-Src messenger RNA (mRNA). This reduction in v-Src protein levels allows researchers to investigate the role of Src signaling in cell proliferation, survival, and motility, as well as its impact on downstream pathways such as PI3K/Akt and MAPK/ERK. While primarily used as a laboratory tool in cell culture and animal models of sarcoma, v-Src siRNA has been instrumental in validating Src as a therapeutic target in oncology.

Other names
v-Src small interfering RNASrc siRNA
02

Targets

AGO2 (Argonaute RISC catalytic component 2)IFIH1 (MDA5)DDX58 (Retinoic acid-inducible gene I protein)TLR3 (Toll-like receptor 3)TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)Rous sarcoma virus v-src oncogene mRNASRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on v-Src siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on v-Src siRNA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call